Alcon Ag · SIX:ALC
Alcon — 42nd Annual J.P. Morgan Healthcare Conference (January 2024)
23 slides from Alcon's conference presentation, Jan 10, 2024
Slide 1: Innovation Update
PAGE 1 JANUARY 10, 2024 JP Morgan Healthcare Conference Innovation Update David Endicott Chief Executive Officer BUSINESS USE ONLY
Slide 2: Safe Harbor
PAGE 2 Safe Harbor Forward-looking statements This document contains, and our officers and representatives may from time to time make, certain “forward-looking statements” within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking sta
Slide 3: Markets & Strategy
JP MORGAN HEALTHCARE CONFERENCE | INNOVATION UPDATE PAGE 3 MARKETS & STRATEGY BUSINESS USE ONLY
Slide 4: Broad Portfolio in Resilient Markets Growing at Mid-Single Digits
DURABLE, RESILIENT MARKETS PAGE 4 BROAD PORTFOLIO IN RESILIENT MARKETS GROWING AT MID-SINGLE DIGITS 2023 INDUSTRY SALES1 ($B) 2023-2028E INDUSTRY CAGR1 TOTAL MARKET $33B 4-5% IMPLANTABLES2 $4 ~6% SURGICAL CONSUMABLES2 $6 $13B ~5% CAGR: ~5% EQUIPMENT / OTHER2 $3 ~6% CONTACT LENSES $11 ~5% VISION CARE
Slide 5: Alcon Growth Accelerated Across Categories in Recent Years from Innovation Wave
GROWTH SUMMARY PAGE 5 ALCON GROWTH ACCELERATED ACROSS CATEGORIES IN RECENT YEARS FROM INNOVATION WAVE ALC CATEGORY GROWTH VS. PRIOR YEAR IN RECENT YEARS Full Year cc growth vs. the prior year, except 2021 which is compared to 2019 9m YTD • Growth increased from in line +11% +11% with market 3-5% to
Slide 6: Alcon Strategy
STRATEGY PAGE 6 Specialty market expertise • Data driven customer insights • Market assessment • Market access & development • Global commercialization ALCON STRATEGY Specialty technology expertise • Optical design and engineering WE FOCUS ON EYE CARE • Clinical endpoints and trial design • Formulat
Slide 7: Vision Care Innovation
JP MORGAN HEALTHCARE CONFERENCE | INNOVATION UPDATE PAGE 7 VISION CARE INNOVATION BUSINESS USE ONLY
Slide 8: Significant Vision Care Product Flow Since Spin
VISION CARE INNOVATION PAGE 8 SIGNIFICANT VISION CARE PRODUCT FLOW SINCE SPIN 2019–2020 2021–2023 2024–2026 for Astigmatism for Astigmatism for Astigmatism Multifocal AR-15512 (DRY EYE DISEASE, PENDING PHASE 3 CLINICALS) Once Daily Extra Strength Twice Daily and Once Daily (US) Complete, Ultra and (
Slide 9: Double Digit Systane MDPF Growth Fueled Strong Ocular Health Gains
VISION CARE INNOVATION PAGE 9 DOUBLE DIGIT SYSTANE MDPF GROWTH FUELED STRONG OCULAR HEALTH GAINS NEW COMBINED STRENGTH OF SYSTANE COMPLETE PLUS OCULAR HEALTH GROWTH HYALURONIC ACID FOR LONGER RELIEF Strong Market Interest1 10% Doctor intent to recommend 86% Rx 2% 10% 1% 10% Consumer OTC 10% 6% Hyalu
Slide 10: Contact Lens: Recent Innovations in Dailies and Reusables Are Winning in the Market
VISION CARE INNOVATION PAGE 10 CONTACT LENS: RECENT INNOVATIONS IN DAILIES AND REUSABLES ARE WINNING IN THE MARKET ALC GLOBAL CONTACT LENS MARKET SHARE EVOLUTION1 ALC CL REVENUE GROWTH VS. PRIOR YEARS ~26%2 ~260 basis points of share growth2 11% DT1 Tor. US launch 9% 1 POINT OF SHARE GROWTH = ~$100M
Slide 11: Rocklatan Total Prescriptions (TRx) Have Been Performing Well
VISION CARE INNOVATION PAGE 11 ROCKLATAN TOTAL PRESCRIPTIONS (TRx) HAVE BEEN PERFORMING WELL MONTHLY TRx - ROCKLATAN 32 • Q3 2023 YTD Unit Growth and Share TOTAL PRESCRIPTIONS (000s) gains (TRx +8% vs. PY, Market +1.5%) 30 28 • Aerie integration complete and sales force trained and aligned 26 24 • E
Slide 12: AR-15512: Primary Endpoint Met in Both COMET Studies
AR-15512 is an investigational product and has VISION CARE INNOVATION not been submitted to US FDA for approval PAGE 12 AR-15512: PRIMARY ENDPOINT MET IN BOTH COMET STUDIES, SUPPORTING PATH TO SEEK FULL INDICATION OF TREATMENT OF SIGNS AND SYMPTOMS OF DED1 COMET-2: PROPORTION WITH ≥10 mm INCREASE IN
Slide 13: AR-15512: Differentiated Product Candidate with Opportunity to Win Share in ~$1.4B U.S. Market
AR-15512 is an investigational product and has VISION CARE INNOVATION not been submitted to US FDA for approval PAGE 13 AR-15512: DIFFERENTIATED PRODUCT CANDIDATE WITH THE OPPORTUNITY TO WIN SHARE IN THE ~$1.4B U.S. MARKET1 DRY EYE DISEASE OPPORTUNITY3 AR-15512 38M • First-in-class product candidate
Slide 14: Surgical Innovation
JP MORGAN HEALTHCARE CONFERENCE | INNOVATION UPDATE PAGE 14 SURGICAL INNOVATION BUSINESS USE ONLY
Slide 15: Significant Surgical Product Flow Since Spin
SURGICAL INNOVATION PAGE 15 SIGNIFICANT SURGICAL PRODUCT FLOW SINCE SPIN 2019–2020 2021–2023 2024–2026 CLAREON IOL FAMILY ROLLOUT (INT’L) NEXT-GEN DIAGNOSTIC NEXT-GEN PHACO-VIT NEXT-GEN CONSUMABLES biometer NEXT-GEN IOLs (US) (International) NEXT-GEN MICROSCOPE List is not exhaustive. New product la
Slide 16: Implantables: Innovation Portfolio
SURGICAL INNOVATION PAGE 16 IMPLANTABLES: INNOVATION PORTFOLIO Combining best-in-class materials, delivery and advanced optics to drive AT-IOL penetration & share Continuing conversion to best-in-class CLAREON US ATIOL PENETRATION1 material Expected to launch Next ESTIMATED US PENETRATION CEILING: ~
Slide 17: Next Generation Vit-Cataract System: Unity VCS
Investigational product: SURGICAL INNOVATION Pending US FDA 510(K) clearance PAGE 17 NEXT GENERATION VIT-CATARACT SYSTEM: UNITY VCS Unprecedented surgical performance in a dual console to drive upgrades and capture share TODAY PIPELINE EMMETROPIA • Designed to create near physiological1 conditions d
Slide 18: Next-Generation Diagnostics: Unity DX
Investigational product: 510K not yet SURGICAL INNOVATION submitted to US FDA for clearance PAGE 18 NEXT-GENERATION DIAGNOSTICS: UNITY DX 6-in-1 “Whole-eye" Analyzer with best-in-market performance at a lower cost Customer Segment Alcon offering 1 Biometer ($30-70k): Primary eye measures for IOL cal
Slide 19: Key Takeaways
KEY TAKEAWAYS PAGE 19 KEY TAKEAWAYS • Deep specialty market and technology expertise in eye care • Broad portfolio of growth drivers • Multiple vectors of growth in resilient markets • Recent product launches driving above-market growth • Major opportunity in contact lenses with new products • Expan
Slide 20: Thank You
PAGE 20 Thank You BUSINESS USE ONLY
Slide 21: Appendix
JP MORGAN HEALTHCARE CONFERENCE | INNOVATION UPDATE PAGE 21 APPENDIX BUSINESS USE ONLY
Slide 22: Contact Lenses: Innovating in Reusables
VISION CARE INNOVATION PAGE 22 CONTACT LENSES: INNOVATING IN REUSABLES Total30 family and Precision7 family Q3 2023 SELL-IN BY MODALITY1 MOST INNOVATIVE REUSABLE ALCON PRODUCTS ~$10.4B, ANNUALIZED ALCON SHARE % ~29% Dailies DD: ~60% Reusable 1-month lens Reusable 1-week lens New chemistry New chemis
Slide 23: A Digital Ecosystem: Digital Cataract Planner
SURGICAL INNOVATION PAGE 23 A DIGITAL ECOSYSTEM: DIGITAL CATARACT PLANNER Alcon’s digital platform simplifies surgeons’ workflow and connects Alcon’s ecosystem CLINIC CATARACT PLANNER OPERATING ROOM Cloud-based digital platform to deliver data exchange, device connectivity & decision support UNITY P
Alcon — 42nd Annual J.P. Morgan Healthcare Conference (January 2024) on 6ix